FibroGen (NASDAQ:FGEN) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of FibroGen (NASDAQ:FGEN) in a report released on Thursday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Separately, William Blair reissued a “market perform” rating on shares of FibroGen in a research note on Wednesday.

FibroGen Price Performance

FibroGen stock opened at $0.33 on Thursday. The company has a market cap of $33.73 million, a P/E ratio of -0.27 and a beta of 0.72. FibroGen has a fifty-two week low of $0.18 and a fifty-two week high of $2.93. The firm’s 50 day simple moving average is $0.36 and its 200-day simple moving average is $0.71.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.21. The firm had revenue of $46.33 million for the quarter, compared to analysts’ expectations of $34.00 million. During the same quarter in the previous year, the firm posted ($0.52) earnings per share. On average, analysts expect that FibroGen will post -1.12 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC grew its holdings in shares of FibroGen by 3.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock valued at $433,000 after acquiring an additional 32,884 shares in the last quarter. FMR LLC boosted its position in FibroGen by 21.8% during the third quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock valued at $153,000 after purchasing an additional 68,569 shares during the last quarter. Assenagon Asset Management S.A. purchased a new position in FibroGen in the third quarter valued at about $307,000. Point72 DIFC Ltd increased its position in FibroGen by 734.2% in the 2nd quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 45,990 shares during the last quarter. Finally, Cubist Systematic Strategies LLC raised its stake in shares of FibroGen by 3,906.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 287,332 shares of the biopharmaceutical company’s stock worth $256,000 after purchasing an additional 280,161 shares in the last quarter. Institutional investors and hedge funds own 72.71% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.